Quincy Chu


Faculty of Medicine & Dentistry - Oncology Dept
(780) 432-8248
Cross Cancer Institute
11560 University Avenue
Edmonton AB
T6G 1Z2


Area of Study / Keywords


I received my BSc in biochemistry at McMaster University, followed by my MD at the University of Toronto.  After I finished my internal medicine and medical oncology training at the University of Western Ontario, I pursued my fellowship training in advanced novel anti-cancer therapeutics at the Institute for Drug Development, San Antonio Texas.  During my fellowship, my main focuses are on early clinical and translational development on novel anti-cancer therapeutics and clinical pharmacology. 


Clinical Interests: My main clinical interests are in the treatment of thoracic malignancies and adult soft tissue and bone sarcomas.

Phase I/II Clinical Research: From 2002 to 2005, I pursued a clinical research fellowship in the development of novel anti-cancer agents, including cytotoxic, molecular targeted and anti-sense DNA agents at the Institute for Drug Development in San Antonio, Texas. In collaboration with my clinical and basic science colleagues, Dr. Michael Sawyer and I are in the midst of formally establishing a New Drug Development Programme at the Cross. Through the role of investigator-in-charge of the Princess Margaret Phase II Consortium, and collaboration with pharmaceutical companies, it will provide us the golden opportunity to study novel anti-cancer agents.

Translational Research in Novel Anti-cancer Agents: Due to the heterogeneity of clinical and molecular characteristics of solid tumours, there is considerable difference in their response and clinical outcome with different anti-cancer therapy. We will perform translational research to identify molecular determinants for response using clinical tumour and serum samples collected through primary surgery and clinical trials and tumour cell lines.

Translational Research in Adult Soft Tissue Sarcomas: Adult soft tissue sarcoma is a class of rare and heterogenous malignant tumours arising from the mesenchymal tissues. The systemic treatment options available in this disease are very limited. Through the collaboration with Polyomx and the Sarcoma Team at the Cross, samples of soft tissue sarcomas are collected for biological studies in order to understand the clinical, biological and molecular characteristics of various soft tissue sarcoma subtypes, and thus better therapeutic options are available in this disease site.


Aside from bedside or more accurate called clinic teaching of rotating medical students, medicine, surgery and pathology residents, medical oncology and respiratory fellows, I teach the basics on clinical trial designs for the medical oncology fellows.  In addition, I coordinate the biannual Clinical Pharmacology series for the medical oncology fellows with Drs. Sawyer and Spratlin. 

I am also a teaching faculty for the Faculty of Agriculture and Nutrition annually on nutritional complications from anti-cancer agents. 

Featured Publications

ASCO (Oral Presentation). 2022 June; 10.1200/JCO.2022.40.16_suppl.2500

Nowak K., Formenti K., Huang J., Bigras G., Chu Q., Adam B.A., Izevbaye I.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2022 June; 148 (6):1325-1336 10.1007/s00432-022-03924-3

Murphy R.A., Darvishian M., Qi J., Chen Y., Chu Q., Vena J., Dummer T.J.B., Le N., Sweeney E., DeClercq V., Grandy S.A., Keats M.R., Cui Y., Awadalla P., Brenner D.R., Bhatti P.

Cancer Causes and Control. 2022 June; 33 (6):913-918 10.1007/s10552-022-01566-x

American Society of Hematology Ann Meeting (Poster). 2022 May; n/a

Herbst R.S., Majem M., Barlesi F., Carcereny E., Chu Q., Monnet I., Sanchez-Hernandez A., Dakhil S., Camidge D.R., Winzer L., Soo-Hoo Y., Cooper Z.A., Kumar R., Bothos J., Aggarwal C., Martinez-Marti A.

Journal of Clinical Oncology. 2022 April; 3 10.1200/JCO.22.00227

Riopel N.D., Chu Q., Walker J., Ye C.

Journal of Immunotherapy. 2022 April; 45 (4):207-209 10.1097/CJI.0000000000000409

Jogiat U.M., Chu Q.S., Nagendran J., Laing B., Hirji A., Adam B.A.

ANTICANCER RESEARCH. 2022 February; 42 (2):1157-1160 10.21873/anticanres.15580

Zhang L., Coffin J., Formenti K., Chu Q., Izevbaye I.

BMJ Open Respiratory Research. 2022 January; 9 (1) 10.1136/bmjresp-2021-001154

Khwaja R.M., Chu Q.S.C.

Current Oncology. 2022 January; 29 (2):479-489 10.3390/curroncol29020043

Cheema P.K., Banerji S.O., Blais N., Chu Q.S.C., Desmeules P., Juergens R.A., Leighl N.B., Sheffield B.S., Wheatley-Price P.F., Melosky B.L.

Current Oncology. 2021 November; 28 (6):4552-4576 10.3390/curroncol28060386

Melosky B., Cheema P., Juergens R.A., Leighl N.B., Liu G., Wheatley-Price P., Sacher A., Snow S., Tsao M.S., McLeod D., Chu Q.

Therapeutic Advances in Medical Oncology. 2021 November; 13 10.1177/17588359211056306

Rottey S., Clarke J., Aung K., Machiels J.P., Markman B., Heinhuis K.M., Millward M., Lolkema M., Patel S.P., De Souza P., Duca M., Curigliano G., Santoro A., Koyama T., Brown M., Vezina H., He C., Siu-Chung Chu Q.

CLINICAL CANCER RESEARCH. 2021 October; 28 (1):95-105 10.1158/1078-0432.CCR-21-1181

Melosky B., Wheatley-Price P., Juergens R.A., Sacher A., Leighl N.B., Tsao M.S., Cheema P., Snow S., Liu G., Card P.B., Chu Q.

Lung Cancer. 2021 October; 160 10.1016/j.lungcan.2021.06.002

Grosjean H.A.I., Dolter S., Meyers D.E., Ding P.Q., Stukalin I., Goutam S., Kong S., Chu Q., Heng D.Y.C., Bebb D.G., Morris D.G., Cheung W.Y., Pabani A.

Current Oncology. 2021 October; 28 (5):4213-4222 10.3390/curroncol28050357

ESMO (Oral Presentation). 2021 September; S1283-S1346. 10.1016/annonc/annonc741

Chu Q.S.c., Bouganim N., Fortier C., Zaknoen S., Stille J.R., Kremer J.D., Yuen E., Hui Y.H., de la Peña A., Lithio A., Smith P.S., Batist G.

Investigational New Drugs. 2021 August; 39 (4):1001-1010 10.1007/s10637-020-01049-3

Journal of Clinical Oncology . 2021 May; 10.1200/JCO.2021.39.15_suppl.2513

Journal of Clinical Oncology . 2021 May; 10.1200/JCO.2021.39.15_suppl.2582

Chu Q.S.c., Bouganim N., Fortier C., Zaknoen S., Stille J.R., Kremer J.D., Yuen E., Hui Y.H., de la Peña A., Lithio A., Smith P.S., Batist G.

Investigational New Drugs. 2021 January; 39 (4):1001-1010 10.1007/s10637-020-01049-3

3. Zhang L, Coffin J, Formenti K, Chu Q, Izevbaye I. Comparative Study of Three Assays: Target Capture Sequencing, MassARRAY and Real-Time qPCR for testing Somatic Mutations in Plasma Cell-Free Circulation Tumour DNA of Non-Small Cell Lung Cancer. AMP 2020: TT10

AMP. 2020 December;

Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial

SITC 2020. 2020 November;

Gutierrez M., Moreno V., Heinhuis K.M., Olszanski A.J., Spreafico A., Ong M., Chu Q., Carvajal R.D., Trigo J., de Olza M.O., Provencio M., de Vos F.Y., de Braud F., Leong S., Lathers D., Wang R., Ravindran P., Feng Y., Aanur P., Melero I.

Clinical Cancer Research. 2020 November; 27 (2):460-472 10.1158/1078-0432.CCR-20-1830

Melosky B., Cheema P.K., Brade A., McLeod D., Liu G., Price P.W., Jao K., Schellenberg D.D., Juergens R., Leighl N., Chu Q.

Oncologist. 2020 November; 25 (11):981-992 10.1634/theoncologist.2020-0193

Chu Q.S.C.

Journal of Thoracic Oncology. 2020 October; 15 (10):1561-1564 10.1016/j.jtho.2020.07.011

van der Meij B.S., Teleni L., Stanislaus A.E., Murphy R.A., Robinson L., Damaraju V.L., Chu Q., Sawyer M.B., Mazurak V.

Clinical Nutrition ESPEN. 2020 October; 40 10.1016/j.clnesp.2020.09.009